Author:
Price David R.,Benedetti Elisa,Hoffman Katherine L.,Gomez-Escobar Luis,Alvarez-Mulett Sergio,Capili Allyson,Sarwath Hina,Parkhurst Christopher N.,Lafond Elyse,Weidman Karissa,Ravishankar Arjun,Cheong Jin Gyu,Batra Richa,Büyüközkan Mustafa,Chetnik Kelsey,Easthausen Imaani,Schenck Edward J.,Racanelli Alexandra C.,Reed Hasina Outtz,Laurence Jeffrey C.,Josefowicz Steven Zvi,Lief Lindsay,Choi Mary E.,Rafii Shahin,Schmidt Frank,Borczuk Alain C.,Krumsiek Jan,Choi Augustine M.K.
Abstract
ABSTRACTVascular injury is a menacing element of acute respiratory distress syndrome (ARDS) pathogenesis. To better understand the role of vascular injury in COVID-19 ARDS, we used lung autopsy immunohistochemistry and blood proteomics from COVID-19 subjects at distinct timepoints in disease pathogenesis, including a hospitalized cohort at risk of ARDS development (“at risk”, N=59), an intensive care unit cohort with ARDS (“ARDS”, N=31), and a cohort recovering from ARDS (“recovery”, N=12). COVID-19 ARDS lung autopsy tissue revealed an association between vascular injury and platelet-rich microthrombi. This link guided the derivation of a protein signature in the at risk cohort characterized by lower expression of vascular proteins in subjects who died, an early signal of vascular limitation termed the maladaptive vascular response. These findings were replicated in COVID-19 ARDS subjects, as well as when bacterial and influenza ARDS patients (N=29) were considered, hinting at a common final pathway of vascular injury that is more disease (ARDS) then cause (COVID-19) specific, and may be related to vascular cell death. Among recovery subjects, our vascular signature identified patients with good functional recovery one year later. This vascular injury signature could be used to identify ARDS patients most likely to benefit from vascular targeted therapies.
Publisher
Cold Spring Harbor Laboratory
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献